DBD — Stock Film
STOCK FILMSCENE 1/11DBD · $67.81
Stock Expert AI presents
DBD
Diebold Nixdorf, Incorporated
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Diebold Nixdorf, Incorporated. A quick introduction.

On the stock market since 2023, it operates in the world of technology. It has 20,000 employees. Now — the numbers.

on the stock market since 2023
20K employees
$2.5B market value
Revenue last year:
$0
The net profit left over:
$0
Out of every $100 in sales, $2 stays as net profit.
THE SLICE THAT TURNS INTO PROFIT: 2%

This is an established company with proven profits.

WHERE DOES THE MONEY COME FROM?
57%Services
Services 57%Products 43%
57% of all revenue comes from a single line: Services.

That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.

Cash on hand:
$0
Total debt:
$0
The debt outweighs the cash.

The gap is $757.7M. In times of high interest rates, a gap like that can squeeze a company.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
59
average

Profit indicators sit around the sector average.

FINANCIAL STRENGTH
26
very weak

Clearly below the class average.

VALUATION
92
very strong

The price looks reasonable next to what the company earns.

GROWTH
93
very strong

This grade is a blend: the profit side is strong, the sales tempo slow.

PRICE MOMENTUM
43
weak

Clearly below the class average.

WORTH WATCHING

Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.

Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 4 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Few are betting against it10/10
WEAK SPOTS
Little set aside for the future2/10
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

R&D Investment: Spending on future research is low.

THE FIVE-YEAR JOURNEY
Below the peak, but no collapse.

The stock trades 25% below its peak. The market has trimmed its expectations for the company.

1
THE BRIGHT SIDE · 1/2
Analysts’ target sits above today’s price

The average analyst price target is $10047% above today’s price.

2
THE BRIGHT SIDE · 2/2
Pays a steady dividend

It pays out $0.40 per share each year — regular cash for whoever holds the stock.

1
THE RISKS · 1/3
A thin financial cushion

The balance sheet offers little cushion against a rough stretch. Report-card grade: 26/100.

2
THE RISKS · 2/3
The stock has lost its spark

Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 43/100. For a turnaround signal, the stock first needs to close the gap with the market.

3
THE RISKS · 3/3
Little set aside for the future

The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.

FINALE · THE GRADE
B
0 / 100 · MoonshotScore

On our five-subject report card, DBD sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”

The takeaway: DBD is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film